An FDA Warning Letter is a notice to a regulated entity citing significant violations and requesting prompt corrective action, typically within 15 business days. Warning letters are usually issued after an inspection where the 483 response was judged inadequate, or after other evidence of significant violations. They are published on FDA's website. Unresolved issues can lead to regulatory actions such as import alerts, seizure, injunction or civil money penalties, and FDA may withhold approval of related Class III submissions. Closure requires FDA to verify corrective actions, often through a follow-up inspection.

Why it matters

Warning Letters are public and can affect new submissions, imports, and reputation. Repeat or unresolved issues can lead to seizures or injunctions.

Common pitfalls

•Assuming a Warning Letter is merely a suggestion, rather than a formal communication of regulatory non-compliance that demands a response.
•Failing to address all cited observations in the Warning Letter, which can lead to further enforcement actions.
•Submitting a response without sufficient evidence or documentation of corrective actions.
•Delaying the response past the specified timeframe, typically 15 business days, without prior communication and agreement with the FDA.
•Underestimating the public and business impact of a Warning Letter, including potential effects on stock prices, contractual agreements, and reputation.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.